Pacira Pharmaceuticals Inc-DE
Open
SectorHealthcare
24.05 2.95
Overview
Share price change
24h
Min
23.32
Max
24.02
Income | 1.3M 2.9M |
|---|---|
Sales | -19M 177M |
P/E Sector Avg | 174.692 50.958 |
EPS | 0.6 |
Profit margin | 1.644 |
Employees | 825 |
EBITDA | 5M 30M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +26.54% upside |
Next Earnings | 4 Aug 2026 |
|---|
Market Cap | -206M 894M |
|---|---|
Previous open | 21.1 |
Previous close | 24.05 |
News Sentiment
By Acuity
67%
33%
290 / 342 Healthcare
Pacira Pharmaceuticals Inc-DE Chart
Past performance is not a reliable indicator of future results.
About Pacira Pharmaceuticals Inc-DE
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.